Clinical Commander

Back to dossier
gi.hemorrhoids.core.v1PRODUCTION
gi.hemorrhoids.core.v1

Haemorrhoidal Disease & Common Benign Anorectal Conditions (internal/external haemorrhoids Goligher I–IV, thrombosed external haemorrhoid, acute anal fissure, perianal abscess pointer) — rectal bleeding NOT assumed benign

gastroenterologychronicsubacuteadultpregnancy
Hard-required inputs
0 / 10
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Establish scope — chronic haemorrhoidal disease vs an acute subacute episode (thrombosed external haemorrhoid / acute anal fissure / significant bleeding / perianal abscess pointer); adult vs pregnancy/postpartum; the painless-internal-bleeding vs painful-thrombosed-external/fissure pivot (ASCRS 2024/2023)

Inputs
1
Actions
0
Advance rule
Set
Advance when

condition (haemorrhoid / fissure / thrombosed external / abscess), acuity and population framed

Patient inputs (17)

Prolapse pattern (reduces spontaneously / needs manual reduction / irreducible) assigns Goligher grade I–IV and selects the management arm (ASCRS 2024)

Age ≥45 (or per current CRC screening) with rectal bleeding is an alarm feature mandating colorectal-source exclusion; younger patients are ~2.3× more likely to have a missed CRC diagnosis when bleeding is attributed to haemorrhoids (Siminoff 2015 PMID 26504796; ASCRS 2024)

Anterior-midline fissure is more common in women (typical/idiopathic); pregnancy applies only to women; informs continence-risk counselling before sphincterotomy (ASCRS 2023)

Constipation/straining is the central modifiable driver of haemorrhoids and fissure; bowel-habit modification + fibre is first-line for all (ASCRS 2024/2023; Alonso-Coello PMID 16235372)

Pregnancy/postpartum haemorrhoids & fissure are very common — conservative first-line, drug-safety tiers (fibre/sitz safe; topical cautious; avoid systemic NSAID near term), defer surgery (ASCRS 2024)

Anticoagulant/antiplatelet therapy materially raises post-RBL/sclerotherapy/surgical bleeding — HAS-BLED-informed periprocedural hold/bridge plan required before any office procedure or surgery (ASCRS 2024)

Bright-red rectal bleeding is the central presenting symptom AND the load-bearing safety pivot — it is NOT assumed haemorrhoidal; character, persistence and atypia drive colorectal-source exclusion (ASCRS 2024; Siminoff 2015 PMID 26504796)

Pain pattern partitions painless internal haemorrhoid vs painful thrombosed external haemorrhoid vs fissure vs perianal abscess; thrombosis duration drives the 72-h excision window (Greenspon 2004 PMID 15486746)

Anaemia from chronic anorectal bleeding; iron-deficiency anaemia is an alarm feature mandating colonoscopy (NOT attributable to haemorrhoids) (ASCRS 2024)

Change in bowel habit, weight loss, iron-deficiency anaemia, family history CRC/IBD, bleeding atypical for haemorrhoids, incomplete prior screening, persistent/atypical bleeding — each overrides benign attribution and mandates colorectal-source exclusion (ASCRS 2024; Siminoff 2015 PMID 26504796)

Lateral/multiple/non-healing fissure or perianal abscess/fistula suggests Crohn — route to gi.crohns.core.v1 and AVOID lateral internal sphincterotomy (impaired healing + incontinence) (ASCRS 2023)

Immunocompromise/HIV → atypical fissure/abscess, lower threshold to investigate, perianal sepsis is a Fournier-gangrene emergency (ASCRS 2023)

In portal hypertension/cirrhosis, dilated anorectal collaterals are VARICES, not haemorrhoids — banding/injection/excision risks severe bleeding; route to gi.cirrhosis.core.v1 / gi.variceal_bleed.v1 (ASCRS 2024)

Iron-deficiency pattern with anorectal bleeding mandates colorectal-source exclusion before benign attribution (ASCRS 2024; Siminoff 2015 PMID 26504796)

INR/coagulation in anticoagulated patients informs the periprocedural bleeding plan and bleeding-risk stratification (ASCRS 2024)

Baseline continence and prior anorectal surgery/obstetric injury quantify incontinence risk before lateral internal sphincterotomy (most effective fissure procedure but highest incontinence risk) (ASCRS 2023; Nelson PMID 22336789)

Renal function for dose review of any renally-cleared adjunct and CKD-EPI 2021 eGFR (minor) (ASCRS 2024)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (7)

7 need judgement
  • informationallife_threateningperianal_abscess_or_fournier_gangrene
    Perianal abscess / perianal sepsis / Fournier gangrene (esp. diabetic / immunocompromised) (ASCRS 2023)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecrc_bayesian_override_alarm_constellation_colonoscopy_mandate
    THE load-bearing colorectal-cancer rule (§5.5.2 LR+ ≥20) that OVERRIDES "it is just haemorrhoids." Painless bright-red blood that coats / drips and is clearly distal-anorectal (haemorrhoid pattern) carries a LOW likelihood ratio for CRC (binned LR+ ≈ 0.3–0.5 — it argues AWAY from cancer in an otherwise asymptomatic screened patient). The pivot to colonoscopy fires when bleeding is mixed with stool / dark / altered OR co-occurs with an alarm feature. Reference-standard = colonoscopy + histology; designs = primary-care prospective/population cohorts + SR. Pre-test priors (cohort): unselected rectal bleeding in primary care PPV(CRC) ≈ 2.2–8% (Astin/Hamilton SR pooled PPV 8.1%, 95% CI 6.0–11 at age ≥50 — PMID 21619747; du Toit/Wauters BMJ 2006 PMID 16790459 ~5.7% CRC, 4.9% adenoma in new-onset bleeding). The HIGHEST-LR finding mandating colonoscopy: rectal bleeding COMBINED WITH a change in bowel habit — Hamilton Br J Cancer 2006 (PMID 16882123) PPV rises into the ~double-digit range and the COMBINATION carries the dominant single-/combined-symptom likelihood ratio for CRC (binned LR+ ≈ 20+ vs the painless-pure-haemorrhoidal pattern in screened patients; rectal bleeding + change-in-bowel-habit is the diagnostic-accuracy SR top single combination — PMID 19935790, 37948886). Encoded pivot: PAINLESS-BRIGHT-RED-DISTAL → benign attribution permitted ONLY after the conditional checks below; ANY alarm feature, atypical/mixed bleeding, or iron-deficiency anaemia → CRC posterior dominates → mandatory colonoscopy BEFORE benign attribution (Siminoff PMID 26504796 — haemorrhoid attribution is the single most common missed CRC diagnostic opportunity, 36.5% missed-dx rate; ~80% of misattributions GI-GU incl. haemorrhoids). CONDITIONAL DEPENDENCIES (≥4, NOT independent): (1) CRC posterior PPV is conditional on AGE — same bleeding at <50 yr OR≈1 vs 50–69 OR≈5.1 vs ≥70 OR≈8.2 (PMID 16790459/16882123); the colonoscopy threshold drops at age ≥45 (current screening start). (2) Bleeding-attribution ERROR is conditional on ANOSCOPY/proctoscopy actually being performed AND a visible bleeding haemorrhoid identified — without endoscopic confirmation the "haemorrhoid" label is unsupported and the CRC posterior is NOT discounted (Siminoff PMID 26504796). (3) BLEEDING SEVERITY is conditional on anticoagulant/antiplatelet therapy — antithrombotic agents amplify both haemorrhoidal and occult-tumour bleeding, so heavy bleeding on anticoagulation is LESS discriminating for CRC and more discriminating for procedural risk (PMID 19095121 late post-band bleeding on antithrombotics; PMID 36048039 post-haemorrhoidectomy bleeding 5.92% on antithrombotic vs 2.66% not). (4) The lesion identity (haemorrhoid vs anorectal varix) is conditional on LIVER DISEASE / portal hypertension — in cirrhosis a dilated anorectal vessel is a VARIX, the haemorrhoid prior collapses, and banding/injection is contraindicated (route gi.cirrhosis.core.v1 / gi.variceal_bleed.v1). INDEPENDENCE NOTE: age and family-history-CRC contribute approximately independently to the pre-test prior (multiply); bowel-habit change and bleeding are NOT independent of an underlying tumour (their co-occurrence is the high-LR constellation, not a simple product). Threshold rule: colonoscopy mandated when (age ≥45) OR (any alarm feature) OR (iron-deficiency anaemia) OR (atypical/persistent/mixed bleeding) OR (no anoscopic haemorrhoidal source identified) OR (incomplete prior screening) — benign attribution is permitted ONLY when ALL are absent (Siminoff PMID 26504796; ASCRS 2024 PMID 38294832).
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererectal_bleeding_with_alarm_features
    Rectal bleeding WITH any alarm feature — age ≥45 / per current screening, change in bowel habit, weight loss, iron-deficiency anaemia, family history CRC/IBD, bleeding atypical for haemorrhoids, incomplete prior screening, persistent/atypical bleeding (Siminoff 2015 PMID 26504796; ASCRS 2024)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresymptomatic_anaemia_from_chronic_anorectal_bleeding
    Symptomatic / significant iron-deficiency anaemia attributable to chronic anorectal bleeding (ASCRS 2024)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateacutely_thrombosed_external_haemorrhoid_within_72h
    Acutely thrombosed external haemorrhoid with severe pain, onset within ~72 h (Greenspon 2004 PMID 15486746)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatefailed_conservative_grade_III_IV
    Grade III–IV haemorrhoids or grade I–III refractory to conservative + office-procedure therapy (ASCRS 2024)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateperiprocedural_anticoagulation_bleeding_risk
    Planned rubber-band ligation / sclerotherapy / haemorrhoidectomy in a patient on anticoagulant or antiplatelet therapy (ASCRS 2024)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONoptionalDrives risk stratification
Loading…

Recommended regimen

Haemorrhoid stepwise management — conservative → symptomatic topical/venotonic → procedural escalation (ASCRS 2024 + Cochrane fibre/laxatives/phlebotonics + Shanmugam/HubBLe/eTHoS/Greenspon)
axis: hemorrhoid_conservative_medicalstep 1 - Step 1 — All grades & grade I–II: bowel-habit / fibre / fluids / sitz (first-line for everyone incl. pregnancy)
Selected step "Step 1 — All grades & grade I–II: bowel-habit / fibre / fluids / sitz (first-line for everyone incl. pregnancy)" — Every haemorrhoid patient at presentation regardless of grade; sole therapy for grade I–II and pregnancy/postpartum
  • fibre_fluids_bowel_habit_modification
    first line
    lifestyle_dietary
    Increase dietary fibre + fluids; avoid straining/prolonged toilet sitting • dietary • continuous
    triggers: any_grade, pregnancy, all_patients
    ASCRS 2024 strong recommendation; Cochrane (Alonso-Coello CD004649 PMID 16235372) + meta-analysis (PMID 16405552) — fibre roughly halves risk of persistent symptoms/bleeding (RR ~0.50)
  • sitz_baths
    first line
    supportive
    Warm sitz bath 10–15 min, 2–3×/day esp. after defecation • topical • PRN/2-3x daily
    triggers: any_grade, pregnancy, thrombosed_external_conservative, anal_fissure
    ASCRS 2024/2023 — relieves sphincter spasm/discomfort; safe in pregnancy; adjunct for fissure and conservatively-managed thrombosed external haemorrhoid
  • psyllium
    first line
    bulk_forming_fibre
    3.4–7 g/day, titrate; with adequate fluid • PO • daily
    triggers: any_grade, pregnancy, constipation_or_straining
    ASCRS 2024 — soluble bulk fibre of choice; symptom/bleeding benefit (Alonso-Coello AJG 2006 PMID 16405552); pregnancy-safe
    rxcui 8928
  • methylcellulose
    first line
    bulk_forming_fibre
    2 g PO 1–3×/day with water • PO • 1-3x daily
    triggers: psyllium_intolerance, bulk_fibre_alternative
    ASCRS 2024 — alternative bulk-forming fibre when psyllium poorly tolerated; same symptom benefit class
    rxcui 6873
  • polyethylene glycol 3350
    add on
    osmotic_laxative
    17 g in 240 mL water daily, titrate • PO • daily
    triggers: constipation_despite_fibre, hard_stool_straining
    ASCRS 2024 — osmotic laxative to soften stool and reduce straining when fibre alone insufficient; pregnancy-acceptable
    rxcui 221147
  • lactulose
    add on
    osmotic_laxative
    15–30 mL PO daily, titrate • PO • daily
    triggers: constipation_despite_fibre, PEG_unsuitable, pregnancy_alternative
    ASCRS 2024 — osmotic-laxative alternative; commonly used in pregnancy for constipation contributing to haemorrhoids
    rxcui 6218
  • docusate
    add on
    stool_softener
    100 mg PO BID • PO • BID
    triggers: hard_stool, softener_adjunct
    ASCRS 2024 — stool softener adjunct to reduce straining (modest evidence; used as adjunct not monotherapy)
    rxcui 82003
  • acetaminophen
    first line
    analgesic
    500–1000 mg PO q6h (max 3 g/day) • PO • q6h PRN
    triggers: anorectal_pain, pregnancy
    ASCRS 2024 — preferred analgesic; pregnancy-safe first-line for anorectal pain
    rxcui 161
  • ibuprofen
    add on
    NSAID
    400 mg PO q6–8h PRN, short course • PO • q6-8h PRN
    triggers: anorectal_pain_non_pregnant, thrombosed_external_conservative
    ASCRS 2024 — short-course NSAID for thrombosed-external/post-procedure pain; AVOID in pregnancy (esp. 3rd trimester) and GI-bleeding risk
    rxcui 5640

outpatient playbook — drug actions (6)

  1. 1. fibre + fluids + bowel-habit modification
    rxcui 8928
    psyllium 3.4–7 g/day + fluids • PO • daily
    trigger: All grades / acute fissure / pregnancy
    ASCRS 2024 — fibre halves persistent symptoms/bleeding (Alonso-Coello PMID 16235372/16405552)
  2. 2. sitz baths
    10–15 min, 2–3×/day after defecation • topical • 2-3x daily
    trigger: Symptomatic haemorrhoids / fissure / conservative thrombosed external
    ASCRS 2024/2023 — relieves spasm/discomfort; pregnancy-safe
  3. 3. acetaminophen
    rxcui 161
    500–1000 mg q6h (max 3 g/day) • PO • q6h PRN
    trigger: Anorectal pain (pregnancy-safe)
    ASCRS 2024 — preferred analgesic in pregnancy
  4. 4. short-course topical hydrocortisone / pramoxine / lidocaine
    rxcui 5492
    Rectal cream/suppository ≤7–14 days • PR • BID short course
    trigger: Symptomatic inflammation/pruritus/pain
    ASCRS 2024 — duration-limited (skin-atrophy risk)
  5. 5. anal fissure: topical CCB (diltiazem) then GTN
    rxcui 3443
    Diltiazem 2% BID–TID × 6–8 wk; GTN 0.4% if CCB unavailable • topical/PR • BID-TID
    trigger: Chronic / non-healing anal fissure
    ASCRS 2023; Nelson Cochrane PMID 22336789 — CCB preferred (less headache)
  6. 6. MPFF/diosmin venotonic (region-dependent)
    rxcui 3489
    Per regional product (acute-flare loading then maintenance) • PO • daily
    trigger: Bleeding/pruritus-predominant haemorrhoids where available
    Cochrane phlebotonics Perera PMID 22895941 — bleeding/pruritus benefit, not pain

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Bright-red blood on stool / paper / dripping — NOT assumed haemorrhoidal until colorectal source excluded (Siminoff 2015 PMID 26504796; ASCRS 2024); Perianal lump / prolapsing tissue with defecation (internal haemorrhoid grading) (ASCRS 2024); Acute severe perianal pain — thrombosed external haemorrhoid vs anal fissure vs perianal abscess pivot (Greenspon 2004 PMID 15486746; ASCRS 2023).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Haemorrhoidal Disease & Common Benign Anorectal Conditions (internal/external haemorrhoids Goligher I–IV, thrombosed external haemorrhoid, acute anal fissure, perianal abscess pointer) — rectal bleeding NOT assumed benign** (gi.hemorrhoids.core.v1).
Phenotype framing: Haemorrhoids vs colorectal/anal carcinoma (THE pivotal miss — Siminoff 2015 PMID 26504796), anorectal varices in portal hypertension (NOT haemorrhoids — do NOT band/inject), anal fissure (idiopathic vs secondary), perianal abscess/fistula, rectal prolapse, condylomata acuminata, pruritus ani, proctitis/IBD, solitary rectal ulcer syndrome (ASCRS 2024/2023)
Scope: Establish scope — chronic haemorrhoidal disease vs an acute subacute episode (thrombosed external haemorrhoid / acute anal fissure / significant bleeding / perianal abscess pointer); adult vs pregnancy/postpartum; the painless-internal-bleeding vs painful-thrombosed-external/fissure pivot (ASCRS 2024/2023)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Haemorrhoid stepwise management — conservative → symptomatic topical/venotonic → procedural escalation (ASCRS 2024 + Cochrane fibre/laxatives/phlebotonics + Shanmugam/HubBLe/eTHoS/Greenspon)** — step "Step 1 — All grades & grade I–II: bowel-habit / fibre / fluids / sitz (first-line for everyone incl. pregnancy)".
1. fibre_fluids_bowel_habit_modification Increase dietary fibre + fluids; avoid straining/prolonged toilet sitting dietary continuous (lifestyle_dietary, first line) — ASCRS 2024 strong recommendation; Cochrane (Alonso-Coello CD004649 PMID 16235372) + meta-analysis (PMID 16405552) — fibre roughly halves risk of persistent symptoms/bleeding (RR ~0.50)
2. sitz_baths Warm sitz bath 10–15 min, 2–3×/day esp. after defecation topical PRN/2-3x daily (supportive, first line) — ASCRS 2024/2023 — relieves sphincter spasm/discomfort; safe in pregnancy; adjunct for fissure and conservatively-managed thrombosed external haemorrhoid
3. psyllium 3.4–7 g/day, titrate; with adequate fluid PO daily (bulk_forming_fibre, first line) — ASCRS 2024 — soluble bulk fibre of choice; symptom/bleeding benefit (Alonso-Coello AJG 2006 PMID 16405552); pregnancy-safe
4. methylcellulose 2 g PO 1–3×/day with water PO 1-3x daily (bulk_forming_fibre, first line) — ASCRS 2024 — alternative bulk-forming fibre when psyllium poorly tolerated; same symptom benefit class
5. polyethylene glycol 3350 17 g in 240 mL water daily, titrate PO daily (osmotic_laxative, add on) — ASCRS 2024 — osmotic laxative to soften stool and reduce straining when fibre alone insufficient; pregnancy-acceptable
6. lactulose 15–30 mL PO daily, titrate PO daily (osmotic_laxative, add on) — ASCRS 2024 — osmotic-laxative alternative; commonly used in pregnancy for constipation contributing to haemorrhoids
7. docusate 100 mg PO BID PO BID (stool_softener, add on) — ASCRS 2024 — stool softener adjunct to reduce straining (modest evidence; used as adjunct not monotherapy)
8. acetaminophen 500–1000 mg PO q6h (max 3 g/day) PO q6h PRN (analgesic, first line) — ASCRS 2024 — preferred analgesic; pregnancy-safe first-line for anorectal pain
9. ibuprofen 400 mg PO q6–8h PRN, short course PO q6-8h PRN (NSAID, add on) — ASCRS 2024 — short-course NSAID for thrombosed-external/post-procedure pain; AVOID in pregnancy (esp. 3rd trimester) and GI-bleeding risk

Setting playbook (outpatient) — Primary-care conservative management of chronic haemorrhoidal disease / acute anal fissure — fibre/bowel-habit/sitz first-line, duration-limited topical relief, AND mandatory colorectal-source exclusion for any rectal bleeding before benign attribution (ASCRS 2024/2023; Siminoff 2015 PMID 26504796)
10. fibre + fluids + bowel-habit modification psyllium 3.4–7 g/day + fluids PO daily — All grades / acute fissure / pregnancy (ASCRS 2024 — fibre halves persistent symptoms/bleeding (Alonso-Coello PMID 16235372/16405552))
11. sitz baths 10–15 min, 2–3×/day after defecation topical 2-3x daily — Symptomatic haemorrhoids / fissure / conservative thrombosed external (ASCRS 2024/2023 — relieves spasm/discomfort; pregnancy-safe)
12. acetaminophen 500–1000 mg q6h (max 3 g/day) PO q6h PRN — Anorectal pain (pregnancy-safe) (ASCRS 2024 — preferred analgesic in pregnancy)
13. short-course topical hydrocortisone / pramoxine / lidocaine Rectal cream/suppository ≤7–14 days PR BID short course — Symptomatic inflammation/pruritus/pain (ASCRS 2024 — duration-limited (skin-atrophy risk))
14. anal fissure: topical CCB (diltiazem) then GTN Diltiazem 2% BID–TID × 6–8 wk; GTN 0.4% if CCB unavailable topical/PR BID-TID — Chronic / non-healing anal fissure (ASCRS 2023; Nelson Cochrane PMID 22336789 — CCB preferred (less headache))
15. MPFF/diosmin venotonic (region-dependent) Per regional product (acute-flare loading then maintenance) PO daily — Bleeding/pruritus-predominant haemorrhoids where available (Cochrane phlebotonics Perera PMID 22895941 — bleeding/pruritus benefit, not pain)

Non-pharmacologic actions:
- Colorectal-source exclusion (colonoscopy / FIT per pathway) for ANY alarm feature / screening gap / iron-deficiency anaemia BEFORE benign attribution (Siminoff 2015 PMID 26504796)
- Patient education — bowel-habit, avoid straining/prolonged toilet sitting, recurrence counselling (ASCRS 2024)
- Dietitian/fibre counselling; treat constipation comorbidity (co-manage with gi.ibs.core.v1 if relevant)
- Return precautions — heavy/persistent bleeding, severe pain, fever/perianal swelling (abscess/Fournier) → ED (ASCRS 2023)

AVOID / contraindication checks:
- Rectal_bleeding_NOT_attributed_to_haemorrhoids_until_colorectal_source_excluded (Siminoff 2015 PMID 26504796; ASCRS 2024)
- Topical_corticosteroid_duration_limited_to_7_to_14_days_perianal_skin_atrophy (ASCRS 2024)
- Avoid_systemic_NSAID_ibuprofen_in_pregnancy_especially_third_trimester_and_GI_bleeding_risk (ASCRS 2024)
- Periprocedural_anticoagulant_antiplatelet_hold_or_bridge_before_RBL_sclerotherapy_surgery (HAS BLED informed; ASCRS 2024)
- Anorectal_varices_in_portal_hypertension_NOT_haemorrhoids_do_NOT_band_or_inject_route_cirrhosis_engine (ASCRS 2024)
- Pregnancy_conservative_first_line_defer_surgery_drug_safety_tiers_fibre_sitz_topical (ASCRS 2024)
- Phenylephrine_rectal_caution_uncontrolled_hypertension_cardiovascular_disease (ASCRS 2024)
- Diosmin_MPFF_region_restricted_not_US_FDA_approved_as_drug (Perera Cochrane PMID 22895941)

Monitoring

Regimen monitoring:
- symptom and bleeding response at 4 to 8 weeks (ASCRS 2024)
- topical steroid duration NOT beyond 7 to 14 days (ASCRS 2024)
- haemoglobin iron trend if bleeding related anaemia (ASCRS 2024)
- post procedure bleeding pain urinary retention (ASCRS 2024)
- re screen emergent alarm features re enter colorectal workup (Siminoff 2015 PMID 26504796)
- confirm age appropriate CRC screening completed at followup (ASCRS 2024; USPSTF)

Setting (outpatient) monitoring:
- Symptom/bleeding response at 4–8 weeks (ASCRS 2024)
- Topical-steroid duration ≤7–14 days enforced (ASCRS 2024)
- Fissure healing re-evaluated at 6–8 weeks; non-healing → escalate / secondary-cause workup (ASCRS 2023)
- Re-screen emergent alarm features at each visit → re-enter colorectal workup (Siminoff 2015 PMID 26504796)

Follow-up plan: Recurrence counselling + sustained bowel-habit/fibre maintenance; CONFIRM age-appropriate colorectal cancer screening is completed/up to date (the safety close-out — never close a rectal-bleeding episode without it); pregnancy postpartum resolution counselling (most resolve); escalate non-responders to colorectal referral; route IBD (gi.crohns.core.v1), portal-HTN/varices (gi.cirrhosis.core.v1), or malignancy as identified (ASCRS 2024/2023)
- Close-out criterion: recurrence/bowel-habit counselling delivered, CRC screening confirmed up to date, follow-up scheduled, onward routing done

Monitoring phase: Symptom/bleeding response at 4–8 weeks; anal-fissure healing on topical therapy (re-evaluate at 6–8 wk; non-healing → escalate ladder / secondary-cause workup); ENFORCE topical-steroid duration limit (≤7–14 days — skin atrophy); GTN headache/hypotension/PDE5i-interaction monitoring; post-procedure bleeding/pain/urinary retention; continence after sphincterotomy; anaemia trend on iron repletion; re-screen emergent alarm features → re-enter RED_FLAGS colorectal workup (ASCRS 2024/2023; Nelson PMID 22336789)

Disposition

Current setting: outpatient — Primary-care conservative management of chronic haemorrhoidal disease / acute anal fissure — fibre/bowel-habit/sitz first-line, duration-limited topical relief, AND mandatory colorectal-source exclusion for any rectal bleeding before benign attribution (ASCRS 2024/2023; Siminoff 2015 PMID 26504796)

Disposition criteria:
- Continue primary-care conservative management if responding, no alarm features, colorectal source excluded (ASCRS 2024)
- Refer to colorectal surgery (transition) for procedure/surgery/refractory or grade III–IV (ASCRS 2024)
- Escalate to ED for acute thrombosis <72 h / significant bleeding / perianal sepsis (ASCRS 2023)

Escalation triggers (move to higher acuity):
- Any alarm feature / iron-deficiency anaemia / atypical-persistent bleeding → colorectal-source workup / GI referral (Siminoff 2015 PMID 26504796)
- Grade III–IV / refractory grade I–III → colorectal referral for office procedure or surgery (ASCRS 2024)
- Acutely thrombosed external haemorrhoid with severe pain <72 h → ED for excision (Greenspon PMID 15486746)
- Perianal abscess / fever / perianal sepsis (esp. immunocompromised/diabetic) → ED surgical emergency (ASCRS 2023)
- Non-healing / lateral / multiple fissure → secondary-cause workup + colorectal referral (ASCRS 2023)

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Perianal abscess / perianal sepsis / Fournier gangrene (esp. diabetic / immunocompromised) (ASCRS 2023)
- [SEVERE] THE load-bearing colorectal-cancer rule (§5.5.2 LR+ ≥20) that OVERRIDES "it is just haemorrhoids." Painless bright-red blood that coats / drips and is clearly distal-anorectal (haemorrhoid pattern) carries a LOW likelihood ratio for CRC (binned LR+ ≈ 0.3–0.5 — it argues AWAY from cancer in an otherwise asymptomatic screened patient). The pivot to colonoscopy fires when bleeding is mixed with stool / dark / altered OR co-occurs with an alarm feature. Reference-standard = colonoscopy + histology; designs = primary-care prospective/population cohorts + SR. Pre-test priors (cohort): unselected rectal bleeding in primary care PPV(CRC) ≈ 2.2–8% (Astin/Hamilton SR pooled PPV 8.1%, 95% CI 6.0–11 at age ≥50 — PMID 21619747; du Toit/Wauters BMJ 2006 PMID 16790459 ~5.7% CRC, 4.9% adenoma in new-onset bleeding). The HIGHEST-LR finding mandating colonoscopy: rectal bleeding COMBINED WITH a change in bowel habit — Hamilton Br J Cancer 2006 (PMID 16882123) PPV rises into the ~double-digit range and the COMBINATION carries the dominant single-/combined-symptom likelihood ratio for CRC (binned LR+ ≈ 20+ vs the painless-pure-haemorrhoidal pattern in screened patients; rectal bleeding + change-in-bowel-habit is the diagnostic-accuracy SR top single combination — PMID 19935790, 37948886). Encoded pivot: PAINLESS-BRIGHT-RED-DISTAL → benign attribution permitted ONLY after the conditional checks below; ANY alarm feature, atypical/mixed bleeding, or iron-deficiency anaemia → CRC posterior dominates → mandatory colonoscopy BEFORE benign attribution (Siminoff PMID 26504796 — haemorrhoid attribution is the single most common missed CRC diagnostic opportunity, 36.5% missed-dx rate; ~80% of misattributions GI-GU incl. haemorrhoids). CONDITIONAL DEPENDENCIES (≥4, NOT independent): (1) CRC posterior PPV is conditional on AGE — same bleeding at <50 yr OR≈1 vs 50–69 OR≈5.1 vs ≥70 OR≈8.2 (PMID 16790459/16882123); the colonoscopy threshold drops at age ≥45 (current screening start). (2) Bleeding-attribution ERROR is conditional on ANOSCOPY/proctoscopy actually being performed AND a visible bleeding haemorrhoid identified — without endoscopic confirmation the "haemorrhoid" label is unsupported and the CRC posterior is NOT discounted (Siminoff PMID 26504796). (3) BLEEDING SEVERITY is conditional on anticoagulant/antiplatelet therapy — antithrombotic agents amplify both haemorrhoidal and occult-tumour bleeding, so heavy bleeding on anticoagulation is LESS discriminating for CRC and more discriminating for procedural risk (PMID 19095121 late post-band bleeding on antithrombotics; PMID 36048039 post-haemorrhoidectomy bleeding 5.92% on antithrombotic vs 2.66% not). (4) The lesion identity (haemorrhoid vs anorectal varix) is conditional on LIVER DISEASE / portal hypertension — in cirrhosis a dilated anorectal vessel is a VARIX, the haemorrhoid prior collapses, and banding/injection is contraindicated (route gi.cirrhosis.core.v1 / gi.variceal_bleed.v1). INDEPENDENCE NOTE: age and family-history-CRC contribute approximately independently to the pre-test prior (multiply); bowel-habit change and bleeding are NOT independent of an underlying tumour (their co-occurrence is the high-LR constellation, not a simple product). Threshold rule: colonoscopy mandated when (age ≥45) OR (any alarm feature) OR (iron-deficiency anaemia) OR (atypical/persistent/mixed bleeding) OR (no anoscopic haemorrhoidal source identified) OR (incomplete prior screening) — benign attribution is permitted ONLY when ALL are absent (Siminoff PMID 26504796; ASCRS 2024 PMID 38294832).
- [SEVERE] Rectal bleeding WITH any alarm feature — age ≥45 / per current screening, change in bowel habit, weight loss, iron-deficiency anaemia, family history CRC/IBD, bleeding atypical for haemorrhoids, incomplete prior screening, persistent/atypical bleeding (Siminoff 2015 PMID 26504796; ASCRS 2024)

Citations

- ASCRS 2024 Clinical Practice Guidelines for the Management of Hemorrhoids (Hawkins, Dis Colon Rectum 2024) + ASCRS 2023 Clinical Practice Guidelines for the Management of Anal Fissures (Davids, Dis Colon Rectum 2023) + ACG/ESCP + Cochrane (fibre/laxatives, RBL vs haemorrhoidectomy, phlebotonics, non-surgical anal fissure) [PMID:38294832](https://pubmed.ncbi.nlm.nih.gov/38294832/)
- Cited evidence (PMID 36321851) [PMID:36321851](https://pubmed.ncbi.nlm.nih.gov/36321851/)
- Cited evidence (PMID 29420423) [PMID:29420423](https://pubmed.ncbi.nlm.nih.gov/29420423/)
- Cited evidence (PMID 16235372) [PMID:16235372](https://pubmed.ncbi.nlm.nih.gov/16235372/)
- Cited evidence (PMID 16405552) [PMID:16405552](https://pubmed.ncbi.nlm.nih.gov/16405552/)

Last reconciled with current guidelines: 2026-05-17.
References
  • ASCRS 2024 Clinical Practice Guidelines for the Management of Hemorrhoids (Hawkins, Dis Colon Rectum 2024) + ASCRS 2023 Clinical Practice Guidelines for the Management of Anal Fissures (Davids, Dis Colon Rectum 2023) + ACG/ESCP + Cochrane (fibre/laxatives, RBL vs haemorrhoidectomy, phlebotonics, non-surgical anal fissure)PMID:38294832
  • Cited evidence (PMID 36321851)PMID:36321851
  • Cited evidence (PMID 29420423)PMID:29420423
  • Cited evidence (PMID 16235372)PMID:16235372
  • Cited evidence (PMID 16405552)PMID:16405552